1. Home
  2. JD vs ONC Comparison

JD vs ONC Comparison

Compare JD & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JD.com Inc.

JD

JD.com Inc.

N/A

Current Price

$29.18

Market Cap

36.6B

ML Signal

N/A

Logo BeiGene Ltd. American Depositary Shares

ONC

BeiGene Ltd. American Depositary Shares

N/A

Current Price

$408.98

Market Cap

40.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JD
ONC
Founded
2006
2010
Country
China
Switzerland
Employees
N/A
12000
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.6B
40.6B
IPO Year
2014
2015

Fundamental Metrics

Financial Performance
Metric
JD
ONC
Price
$29.18
$408.98
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
35
27
Target Price
$38.93
★ $437.57
AVG Volume (30 Days)
★ 8.0M
356.4K
Earning Date
11-17-2026
11-05-2026
Dividend Yield
★ 3.49%
N/A
EPS Growth
N/A
★ 140.43
EPS
N/A
★ 0.56
Revenue
N/A
★ $238,387,000.00
Revenue This Year
$2.90
$26.55
Revenue Next Year
$5.50
$14.91
P/E Ratio
★ $9.17
$674.61
Revenue Growth
N/A
★ 22179.16
52 Week Low
$24.51
$253.95
52 Week High
$34.30
$388.66

Technical Indicators

Market Signals
Indicator
JD
ONC
Relative Strength Index (RSI) 73.23 68.35
Support Level $28.25 $335.44
Resistance Level $29.95 N/A
Average True Range (ATR) 0.51 10.85
MACD 0.41 2.30
Stochastic Oscillator 96.96 96.48

Price Performance

Historical Comparison
JD
ONC

About JD JD.com Inc.

JD.com is the third-largest Chinese e-commerce platform by gross merchandise volume in 2025. It offers a wide selection of authentic products with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace, and omnichannel businesses.

About ONC BeiGene Ltd. American Depositary Shares

Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.

Share on Social Networks: